Insulin degludec (Tresiba®) is an ultra-long acting basal insulin analog recently marketed in Belgium. Controlled clinical trials have demonstrated that insulin degludec provides similar reductions in HbA1c compared to the basal analogs glargine or detemir in Type 1 and Type 2 diabetes, with superior fasting glucose control in the majority of studies. The data additionally show a clinically relevant reduction in the incidence of hypoglycemia episodes, especially at night. The results of controlled and observational studies point towards the therapeutic added value of degludec in the management of Type 1 and Type 2 diabetes.
Key Words
Insulin degludec, insulin glargine U100, insulin glargine U300, Type 1 diabetes, Type 2 diabetes, hypoglycemia, HbA1c